Migtan (Sumatriptan)

Sumatriptan, the active ingredient in Migtan, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Migtan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides batch‑tested products with full documentation for regulatory review. Migtan is distributed through a secure supply chain ensuring product integrity from manufacturing to end‑user.

Sumatriptan is a triptan medication used to treat migraine by targeting serotonergic pathways.

- Migraine attack: rapid relief of headache pain, nausea, photophobia and phonophobia. - Migraine with aura: alleviates headache phase following visual or sensory aura. - Migraine without aura: reduces severity and duration of headache when taken early in the attack.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient feeling of light‑headedness. - Tingling or paresthesia: often in the face or extremities. - Chest discomfort: sensation of pressure or tightness. - Fatigue: general feeling of tiredness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Coronary vasospasm: chest pain due to reduced coronary blood flow. - Severe hypertension: sudden increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with serotonergic agents. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm. - Myocardial infarction: rare heart attack in susceptible individuals.

Before prescribing Sumatriptan, clinicians should evaluate the following: - Cardiovascular assessment: avoid use in patients with uncontrolled hypertension or known coronary artery disease. - Hemiplegic migraine: contraindicated due to risk of cerebrovascular events. - Concomitant ergotamine: avoid co‑administration to reduce vasospasm risk. - Serotonergic drugs: monitor for signs of serotonin syndrome when used with SSRIs, SNRIs or MAO inhibitors. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sumatriptan may interact with several drug classes. Awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects. - Ergot alkaloids: heightened vasospasm potential. - SSRIs/SNRIs: potential for serotonin syndrome. - Serotonin‑releasing agents: increased serotonergic toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood pressure lowering. - CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan plasma levels. - Oral contraceptives: slight increase in migraine frequency. - Antihistamines: may augment dizziness. - Certain antibiotics (e.g., erythromycin): modest effect on metabolism.